NetScientific PLC (NSCI) - Vortex Announces Partnership with BioView
13 March 2018 - 9:18PM
ADVFN NewsWire
NetScientific
plc
("NetScientific" or the "Company" or
the "Group")
Vortex
Biosciences and BioView Announce Collaboration for Clinical
Biomarker Identification on Circulating Tumor
Cells
London, UK - 13 March 2018 -- ADVFN
NewsWire -- NetScientific plc
("NetScientific",AIM:NSCI), the transatlantic
healthcare IP commercialisation group, notes that its portfolio
company, Vortex BioSciences, has announced a collaboration
with BioView Ltd (TASE:BIOV), a provider of automated cell imaging
and analysis solutions.
The collaboration will enable Vortex and Bioview to create
integrated workflows that will allow the collection of intact CTCs from blood samples to become part of the
standard of care, with a view to increasing the prominence of CTCs
in the clinical space as a diagnostic and monitoring tool. The aim
of the collaboration is to provide clinicians with deeper insights
into cancer biology.
BioView (TLV: BIOV) is a publicly traded company on the Tel Aviv
Stock exchange, and currently has strategic collaborations underway
with international scientific leaders and institutions. Bioview
develops, manufactures and supplies cell imaging equipment, and
analysis software to medical institutes and universities. It
currently has several strategic collaborations with international
scientific leaders and institutions. BioView's
circulating tumour cell (CTC) application incorporates field-proven
algorithms, developed in collaboration with leading cancer research
centers worldwide.
The integrated VTX-1 and BioView workflow is currently being
used in several clinical studies focused on CTC enumeration, ALK
FISH rearrangements and PD-L1 expression on CTCs. PD-L1, in
particular, has been a focus of the collaboration because of the
potential clinical benefits. Overexpression of PD-L1 has been
identified as a pathway that metastatic tumor cells use to evade
immune detection.
Commenting on the news, Francois
Martelet, Chairman of Vortex BioSciences Inc. and CEO of
NetScientific said: "This
partnership with BioView will allow automated identification of
biomarkers expressed by CTCs collected by Vortex's platform. This
technology has potential applications in the
fast-evolving field of immuno-oncology and the collaboration
represents a critical step for Vortex as it moves
towards the clinical market."
# # #
For more information, please
contact:
NetScientific
François R. Martelet, M.D., CEO
Ian Postlethwaite, CFO
|
Tel: +44 (0)20 3514 1800
|
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson /
Chris Welsh / Laura Thornton
|
Tel: +44 (0)20 3709 5700
netscientific@consilium-comms.com
|
Stifel Nicolaus Europe Limited (NOMAD and Broker)
Jonathan Senior / David Arch / Ben Maddison
Vortex Biosciences
Steve Crouse
|
Tel: +44 (0) 20 7710 7600
Tel: +1 (0) 415 823 7649
steve@vortexbiosciences.com
|
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
MEDIA CONTACT
Steve Crouse
415-823-7649
steve@vortexbiosciences.com
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024